A medium-to-long acting sulfonylurea anti-diabetic drug.
Classified as a third-generation sulfonylurea.
GI absorption is complete, with no interference of meals.
Distributed throughout the body bound to the plasma protein to an extent of 99.5%.
Metabolized by oxidative biotransformation and 60% is excreted in the urine, the remaining being excreted in the feces.
Acts as an insulin secretagogue, and lowers blood sugar by stimulating the release of insulin by pancreatic beta cells.
Induces increased activity of intracellular insulin receptors.
Incidence of hypoglycemia of 2-4%.